Open access
Open access
Powered by Google Translator Translator

Cardio-oncology

Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy

26 Jan, 2023 | 12:09h | UTC

Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy – JACC: CardioOncology

Commentary: Preexisting Autoimmune Disease and Risk for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy for Cancer – The ASCO Post

 


Cohort Study | Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor–induced myocarditis

24 Jan, 2023 | 14:16h | UTC

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis – JACC: CardioOncology

Editorial: Biomarkers for Immune Checkpoint Inhibitor–Induced Myocarditis: Caution Needed – JACC: CardioOncology

News Release: New biomarker strategy devised to screen for, diagnose deadly heart complication from cancer treatment – University of Michigan

Commentary: Biomarker Trends of Immune Checkpoint Inhibitor–Induced Myocarditis – American College of Cardiology

 

Commentary from the author on Twitter

 


AHA Statement | Cancer therapy-related hypertension

23 Jan, 2023 | 13:46h | UTC

Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association – Hypertension

Top Things to Know: Cancer Therapy-Related HTN – American Heart Association

Commentary: Cancer and hypertension induced by anticancer drugs: The need for increased awareness, improved detection and proactive management – American Heart Association

 


The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology

9 Jan, 2023 | 14:08h | UTC

The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology – European Heart Journal

 

Commentary on Twitter

 


Consensus Paper | Evaluation and management of cancer patients presenting with acute cardiovascular diseases.

9 Dec, 2022 | 13:28h | UTC

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology—part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias – European Heart Journal. Acute Cardiovascular Care

See also: Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Related:

The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology.

#ESCCongress | 2022 ESC Guidelines on cardio-oncology.

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations – Annals of Oncology

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association – Circulation

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations – Revista Espanola de Cardiologia

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia

AHA Statement: Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

 


Review | AL Amyloidosis for Cardiologists.

6 Dec, 2022 | 13:36h | UTC

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology.

29 Nov, 2022 | 14:13h | UTC

The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology – European Journal of Cardiology

Original guideline: #ESCCongress | 2022 ESC Guidelines on cardio-oncology.

 


RCT | Effects of a physical exercise intervention during vs. after chemotherapy to improve cardiorespiratory fitness.

23 Nov, 2022 | 14:01h | UTC

Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy – JACC: CardioOncology

Editorial: Inclusion of Exercise in Cancer Treatment Planning: When Is the Right Time? – JACC: CardioOncology

Commentary: Exercise Intervention During Chemotherapy Beneficial – HealthDay

 


Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.

3 Nov, 2022 | 13:39h | UTC

Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

Commentaries:

Sinoatrial Node Radiation During CRT May Increase Risk of Atrial Fibrillation in SCLC and NSCLC – Cancer Network

Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News

 

Commentary on Twitter

 


Systematic Review | Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.

21 Oct, 2022 | 12:47h | UTC

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines – Cochrane Library

Summary: Can the medicine dexrazoxane prevent or reduce heart damage in adults and children with cancer receiving anthracyclines? – Cochrane Library

 


Expert Consensus | Cardiac computed tomographic imaging in cardio-oncology.

14 Oct, 2022 | 14:14h | UTC

Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS) – Journal of Cardiovascular Computed Tomography

 

Commentary on Twitter

 


Review | Permissive cardiotoxicity: the clinical crucible of cardio-oncology.

13 Oct, 2022 | 13:35h | UTC

Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology – JACC: CardioOncology

 


Cohort Study | Cardiovascular morbidity in monoclonal gammopathy of undetermined significance.

13 Oct, 2022 | 13:34h | UTC

Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study – JACC: CardioOncology

Editorial: Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental? – JACC: CardioOncology

 


Consensus recommendations for screening and managing childhood cancer survivors at risk for cardiomyopathy.

11 Oct, 2022 | 13:35h | UTC

Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy – JACC: CardioOncology

Related:

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors – Journal of Clinical Oncology

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) – European Heart Journal – Cardiovascular Imaging

Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations – Annals of Oncology

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association – Circulation

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations – Revista Espanola de Cardiologia

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia

AHA Statement: Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

 


Consensus Statement | Cardiac computed tomographic imaging in cardio-oncology.

22 Sep, 2022 | 13:07h | UTC

Cardiac Computed Tomographic Imaging in Cardio-Oncology: An Expert Consensus Statement from the Society of Cardiovascular Computed Tomography, Endorsed by the International Cardio-Oncology Society (ICOS) – Journal of Cardiovascular Computed Tomography

 

Commentary on Twitter

 


Large study unravels the risk factors for heart failure among childhood cancer survivors.

11 Sep, 2022 | 22:22h | UTC

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors – Journal of Clinical Oncology

 


Review | Cardiovascular complications of immune checkpoint inhibitors for cancer.

6 Sep, 2022 | 14:20h | UTC

Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal

Related:

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

 

Commentary on Twitter

 


#ESCCongress | 2022 ESC Guidelines on cardio-oncology.

29 Aug, 2022 | 12:17h | UTC

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) – European Heart Journal – Cardiovascular Imaging

News Release: Advice to prevent heart problems caused by cancer therapy published today – European Society of Cardiology

Related guidelines:

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations – Annals of Oncology

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association – Circulation

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations – Revista Espanola de Cardiologia

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia

AHA Statement: Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

 


Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.

11 Aug, 2022 | 11:54h | UTC

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes – JAMA Network Open

 

Commentary on Twitter

 


Cohort Study | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients.

28 Jul, 2022 | 13:13h | UTC

Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study – The Aging Male

News Release: Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease – Taylor & Francis

 


Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.

27 Jul, 2022 | 11:53h | UTC

Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer

Commentaries:

People with early-stage Hodgkin lymphoma face a higher risk of dying from cardiovascular disease than from cancer – Wiley

CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay

 


Retrospective Cohort Study | Major adverse cardiovascular events in patients with renal cell carcinoma treated with targeted therapies.

21 Jul, 2022 | 12:54h | UTC

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies – JACC: CardioOncology

Editorial: Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies – JACC: CardioOncology

 


Review | Cardiometabolic comorbidities in cancer survivors.

19 Jul, 2022 | 13:17h | UTC

Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review

 


Review | Cardiovascular disease in myeloproliferative neoplasms.

14 Jul, 2022 | 12:38h | UTC

Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


How to treat renal cell carcinoma: the current treatment landscape and cardiovascular toxicities.

14 Jul, 2022 | 12:35h | UTC

How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities – JACC: CardioOncology

Related: Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis – The Journal of Urology

 


Stay Updated in Your Specialty

No spam, just news.